l e t t e r s
The RNA-programmable Cas9 endonuclease cleaves doublestranded DNA at sites complementary to a 20-base-pair guide RNA. The Cas9 system has been used to modify genomes in multiple cells and organisms, demonstrating its potential as a facile genome-engineering tool. We used in vitro selection and high-throughput sequencing to determine the propensity of eight guide-RNA:Cas9 complexes to cleave each of 10 12 potential off-target DNA sequences. The selection results predicted five off-target sites in the human genome that were confirmed to undergo genome cleavage in HEK293T cells upon expression of one of two guide-RNA:Cas9 complexes. In contrast to previous models, our results show that guide-RNA:Cas9 specificity extends past a 7-to 12-base-pair seed sequence. Our results also suggest a tradeoff between activity and specificity both in vitro and in cells as a shorter, less-active guide RNA is more specific than a longer, moreactive guide RNA. High concentrations of guide-RNA:Cas9 complexes can cleave off-target sites containing mutations near or within the PAM that are not cleaved when enzyme concentrations are limiting.
Sequence-specific endonucleases including zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) have become important tools to modify genes in induced pluripotent stem cells (iPSCs) [1] [2] [3] , in multicellular organisms [4] [5] [6] [7] [8] , and in ex vivo gene therapy clinical trials 9 (NCT00842634, NCT01044654, NCT01252641). Although ZFNs and TALENs have proved effective for such genetic manipulation, a new ZFN or TALEN protein must be generated for each DNA target site. By contrast, the RNA-guided Cas9 endonuclease uses RNA:DNA hybridization to find target DNA cleavage sites, enabling a single monomeric protein to cleave, in principle, any sequence specified by the guide RNA 10 .
Previous studies [11] [12] [13] [14] [15] [16] demonstrated that Cas9 mediates genome editing at sites complementary to a 20-nucleotide sequence in a bound guide RNA. In addition, target sites must include a protospacer adjacent motif (PAM) at the 3′ end adjacent to the 20-base-pair target site; for Streptococcus pyogenes Cas9, the PAM sequence is NGG. Cas9-mediated DNA cleavage specificity both in vitro and in cells has been inferred previously based on assays against small collections of potential single-mutation off-target sites. These studies suggested that perfect complementarity between guide RNA and target DNA is required in the 7-12 base pairs adjacent to the PAM end of the target site (3′ end of the guide RNA) and mismatches are tolerated at the non-PAM end (5′ end of the guide RNA) 10, 11, [16] [17] [18] .
Although with such a limited number of nucleotides specifying guide-RNA:Cas9 target recognition one would predict multiple sites of DNA cleavage in genomes of moderate to large size (>~10 7 bp), guide-RNA:Cas9 complexes have been successfully used to modify both cells 11, 12, 14 and organisms 13 . A study using guide-RNA:Cas9 complexes to modify zebrafish embryos found toxicity at a rate similar to that of ZFNs and TALENs 13 . A recent, broad study of the specificity of DNA binding (transcriptional repression) in Escherichia coli of a catalytically inactive Cas9 mutant using high-throughput sequencing found no detectable off-target transcriptional repression in the relatively small E. coli transcriptome 19 . Although these studies have substantially advanced our basic understanding of Cas9, a systematic and comprehensive profile of guide-RNA:Cas9-mediated DNA cleavage specificity generated from measurements of Cas9 cleavage on a large number of related mutant target sites has not been described. Such a specificity profile is needed to understand and improve the potential of guide-RNA:Cas9 complexes as research tools and future therapeutic agents.
To determine the off-target DNA cleavage profiles of single guide RNA (sgRNA):Cas9 (ref. 10) complexes, we modified our previously published in vitro selection protocol 20 to process the blunt-ended cleavage products produced by Cas9 instead of the overhangcontaining products of ZFN cleavage. Each selection experiment used DNA substrate libraries containing ~10 12 sequences, a size sufficiently large to include tenfold coverage of all sequences with eight or fewer mutations relative to each 22-base-pair target sequence (including the two-base-pair PAM) ( Fig. 1) . We used partially randomized nucleotide mixtures at all 22 target-site base pairs to create a binomially distributed library of mutant target sites with an expected mean of 4.62 mutations per target site. In addition, target site library members were flanked by four fully randomized base pairs on each side to test for specificity patterns beyond those imposed by the canonical 20-base-pair target site and PAM.
Pre-selection libraries of >10 12 individual potential off-target sites were generated for each of four different target sequences in the human clathrin light chain A (CLTA) gene ( Supplementary Fig. 1 ). l e t t e r s Synthetic 5′-phosphorylated, 53-base oligonucleotides were selfligated into circular single-stranded DNA in vitro and then converted into concatemeric 53-base-pair repeats through rolling-circle amplification. The resulting pre-selection libraries were incubated with their corresponding sgRNA:Cas9 complexes. Cleaved library members containing free 5′ phosphates were separated from intact library members through the 5′ phosphate-dependent ligation of nonphosphorylated, double-stranded sequencing adapters. The ligationtagged post-selection libraries were amplified by PCR. The PCR step generated a mixture of post-selection DNA fragments containing, e.g., 0.5, 1.5, or 2.5 repeats of library members cleaved by Cas9, resulting from amplification of an adapter-ligated cut half-site with or without one or more adjacent corresponding full sites ( Fig. 1) . Post-selection library members with 1.5 target-sequence repeats were isolated by gel purification and analyzed by high-throughput sequencing. In a final computational selection step to minimize the impact of errors during DNA amplification or sequencing, only sequences with two identical copies of the repeated cut half-site were analyzed.
Two guide RNA constructs were assayed in the in vitro selection 14 . Pre-selection libraries were incubated under enzyme-limiting conditions (200 nM target site library, 100 nM sgRNA v2.1:Cas9) or enzymeexcess conditions (200 nM target site library, 1,000 nM sgRNA v2.1: Cas9) for each of the four guide RNA targets tested (CLTA1, CLTA2, CLTA3 and CLTA4) ( Supplementary Fig. 1c,d) . A second guide RNA construct, sgRNA v1.0, which is less active than sgRNA v2.1, was assayed under enzyme-excess conditions alone for each of the four guide RNA targets tested (200 nM target site library, 1,000 nM sgRNA v1.0:Cas9). The two guide RNA constructs differed in their length ( Supplementary  Fig. 1 ) and in their DNA cleavage activity level under the selection conditions, consistent with previous reports 14 (Supplementary Fig. 2 ). Both pre-selection and post-selection libraries were characterized by high-throughput DNA sequencing and computational analysis. As expected, library members with fewer mutations were significantly enriched in post-selection libraries relative to pre-selection libraries (P ~ 0; Supplementary Notes and Supplementary Fig. 3) .
We calculated specificity scores to quantify the enrichment level of each base pair at each position in the post-selection library relative to that of the pre-selection library, normalized to the maximum possible enrichment of that base pair. Positive specificity scores indicate base pairs that were enriched in the post-selection library and negative specificity scores indicate base pairs that were de-enriched in the postselection library. For example, a score of +0.5 indicates that a base pair is enriched to 50% of the maximum enrichment value, whereas a score of −0.5 indicates that a base pair is de-enriched to 50% of the maximum de-enrichment value.
In addition to the two base pairs specified by the PAM, all 20 base pairs targeted by the guide RNA were enriched in the sequences from the CLTA1 and CLTA2 selections ( Fig. 2, Supplementary Figs. 4 and 7, and Supplementary Table 1 ). For the CLTA3 and CLTA4 selections (Supplementary Figs. 5 and 6, and Supplementary Table 1 ), guide RNA-specified base pairs were enriched at all positions except for the one or two base pairs most distal from the PAM (5′ end of the guide RNA), respectively. At these nonspecified positions farthest from the PAM, at least two of the three alternate base pairs were nearly as enriched as the specified base pair. Our finding that the entire 20-base-pair target site and two-base-pair PAM can contribute to sgRNA:Cas9 DNA cleavage specificity contrasts with the results from previous single-substrate assays, suggesting that only 7-12 base pairs and two-base-pair PAM are specified 10, 11, 14 .
All single-mutant pre-selection (n ≥ 14,569) and post-selection library members (n ≥ 103,660) were computationally analyzed to provide a selection enrichment value for every possible single-mutant sequence. The results of this analysis ( Fig. 2 and Supplementary  Figs. 4-6) show that when only single-mutant sequences are considered, the six to eight base pairs closest to the PAM are generally highly Figure 1 In vitro selection overview. (a) Cas9, complexed with an sgRNA recognizes ~20 bases of a target DNA substrate that is complementary to the sgRNA sequence, cleaves both DNA strands. The white triangles represent cleavage locations. (b) A modified version of our previously described in vitro selection 20 was used to comprehensively profile Cas9 specificity. Concatemeric pre-selection DNA libraries in which each molecule contains one of >10 12 distinct variants of a target DNA sequence (white rectangles) were generated from synthetic DNA oligonucleotides by ligation and rolling-circle amplification. Each library was incubated with sgRNA:Cas9 complexes of interest. Cleaved library members contain 5′ phosphate groups (green circles) and therefore are substrates for adapter ligation and PCR. The resulting amplicons were subjected to high-throughput DNA sequencing and computational analysis. l e t t e r s specified and the non-PAM end is poorly specified under enzymelimiting conditions, consistent with previous findings 10, 11, [16] [17] [18] . Under enzyme-excess conditions, however, single mutations even in the six to eight base pairs most proximal to the PAM are tolerated, suggesting that the high specificity at the PAM end of the DNA target site can be compromised when enzyme concentrations are high relative to substrate (Fig. 2) . The observation of strong discrimination against single mutations close to the PAM applies only to sequences with a single mutation, and the selection results do not support a model in which any combination of mutations is tolerated in the region of the target site farthest from the PAM (Supplementary Notes and  Supplementary Figs. 8-15 ). See the Supplementary Notes for analyses of pre-and post-selection library composition, positiondependent specificity patterns (Supplementary Figs. 16-18) , PAM nucleotide specificity (Supplementary Figs. 19-22) , and more detailed effects of sgRNA:Cas9 concentration on specificity ( Fig. 2g  and Supplementary Fig. 23) .
The selection results also reveal that the choice of guide RNA structure affects cleavage of off-target sites. The shorter, less-active sgRNA v1.0 constructs are less tolerant of mutations than the longer, more-active sgRNA v2.1 constructs when assayed under identical, enzyme-excess conditions that reflect a cellular context of excess of enzyme relative to substrate ( Fig. 2 and Supplementary Figs. 3-6) . The difference in off-target activity between sgRNA v1.0 and sgRNA v2.1 is greater for CLTA1 and CLTA2 (~40-90% difference) than for CLTA3 and CLTA4 (<40% difference). The differences in tolerated off-target mutations between sgRNA constructs are localized to different regions of the target site for each target sequence ( Fig. 2h  and Supplementary Fig. 24) . Collectively, these results indicate that different guide RNA architectures result in different off-target DNA cleavage activities, and that guide RNA-dependent changes in specificity do not affect all positions in the target site equally. Given the inverse relationship between sgRNA:Cas9 concentration and specificity described above, we speculate that the differences in off-target activities between guide RNA architectures arises from differences in their overall level of DNA-cleavage activities.
To confirm that the in vitro selection results accurately reflect the cleavage behavior of Cas9 in vitro, we performed discrete cleavage npg l e t t e r s assays of six CLTA4 off-target substrates containing one to three mutations in the target site. We calculated enrichment values for all sequences in the post-selection libraries for the CLTA4 v2.1 sgRNA: Cas9 selection under enzyme-excess conditions by dividing the abundance of each sequence in the post-selection library by the calculated abundance in the pre-selection library. Under enzyme-excess conditions, the single one-, two-and three-mutation sequences with the highest enrichment values (27.5, 43.9 and 95.9) were cleaved to ≥72% completion (Supplementary Fig. 25) . A two-mutation sequence with an enrichment value of 1.0 was cleaved to 35%, and a two-mutation sequence with an enrichment value near zero (0.064) was not cleaved. The three-mutation sequence, which was cleaved to 77% by CLTA4 sgRNA v2.1, was cleaved to a lower efficiency of 53% by CLTA4 sgRNA v1.0 (Supplementary Fig. 26) . These results indicate that the selection enrichment values of individual sequences are predictive of in vitro cleavage efficiencies.
To determine if results of the in vitro selection and in vitro cleavage assays pertain to guide-RNA:Cas9 activity in human cells, we identified 51 off-target sites (19 for CLTA1 and 32 for CLTA4) containing up to eight mutations that were both enriched in the in vitro selection and present in the human genome (Supplementary Tables 2-4) . We expressed CLTA1 sgRNA v1.0:Cas9, CLTA1 sgRNA v2.1:Cas9, CLTA4 sgRNA v1.0:Cas9, CLTA4 sgRNA v2.1:Cas9 or Cas9 without sgRNA in HEK293T cells by transient transfection and used genomic PCR and high-throughput DNA sequencing to look for evidence of sgRNA: Cas9 modification at 46 of the 51 off-target sites as well as at the ontarget loci; no specific amplified DNA was obtained for 5 of the 51 predicted off-target sites (3 for CLTA1 and 2 for CLTA4).
Deep sequencing of genomic DNA isolated from HEK293T cells treated with CLTA1 sgRNA:Cas9 or CLTA4 sgRNA:Cas9 identified sequences evident of end-joining (NHEJ) at the on-target sites and at 5 of the 49 tested off-target sites (CLTA1-1-1, CLTA1-2-2, CLTA4-3-1, CLTA4-3-3 and CLTA4-4-8) (Table 1 and Supplementary Tables 5-7) . The CLTA4 target site was modified by CLTA4 sgRNA v2.1:Cas9 at a frequency of 76%, whereas off-target sites, CLTA4-3-1, CLTA4-3-3 and CLTA4-4-8, were modified at frequencies of 24%, 0.47% and 0.73%, respectively. The CLTA1 target site was modified by CLTA1 sgRNA v2.1:Cas9 at a frequency of 0.34%, whereas off-target sites, CLTA1-1-1 and CLTA1-2-2, were modified at frequencies of 0.09% and 0.15%, respectively.
Under enzyme-excess conditions with the sgRNA v2.1, the two verified CLTA1 off-target sites, CLTA1-1-1 and CLTA1-2-2, were two of the three most highly enriched sequences identified in the in vitro selection. CLTA4-3-1 and CLTA4-3-3 were the highest and third-highest enriched sequences of the seven CLTA4 three-mutation sequences enriched in the in vitro selection that are also present in the genome. The in vitro selection enrichment values of the 
GCcagaaTAGTtTTTCaACAAGG SEPHS2 0% 0.00% 0.007% CLTA4-7-2 8 ttgtATtTAGaGaTTgCACAAGG RORB 0% 0.00% 0% 33 human genomic DNA sequences were identified that were enriched in the CLTA4 sgRNA v2.1:Cas9 in vitro selections under enzyme-limiting or enzyme-excess conditions. Sites shown in red contain insertions or deletions (indels) that are consistent with substantial sgRNA:Cas9-mediated modification in HEK293T cells. In vitro enrichment values for selections with CLTA4 sgRNA v1.0:Cas9 or CLTA4 sgRNA v2.1:Cas9 are shown for sequences with three or fewer mutations. Enrichment values were not calculated for sequences with four or more mutations due to low numbers of in vitro selection sequence counts. Modification frequencies (number of sequences with indels divided by total number of sequences) in HEK293T cells treated with Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA4 sgRNA v1.0, or Cas9 with CLTA4 sgRNA v2.1. P-values are listed for those sites that show substantial modification in sgRNA v1.0-or sgRNA v2.1-treated cells compared to cells treated with Cas9 without sgRNA. P-values were calculated using a one-sided Fisher exact text. "Not tested (n.t.)" indicates that PCR of the genomic sequence failed to provide specific amplification products. l e t t e r s four-mutation sequences were not calculated because 12 out of the 14 CLTA4 sequences in the genome containing four mutations, including CLTA4-4-8, were observed at a level of only one sequence count in the post-selection library. Taken together, these results confirm that several of the off-target substrates identified in the in vitro selection that are present in the human genome are indeed cleaved by sgRNA: Cas9 complexes in human cells and also suggest that the most highly enriched genomic off-target sequences in the selection are modified in cells to the greatest extent. The off-target sites we identified in cells were among the most highly enriched in our in vitro selection and contain up to four mutations relative to the intended target sites. Although it is possible that heterochromatin or covalent DNA modifications could diminish the ability of a guide-RNA:Cas9 complex to access genomic off-target sites in cells, the identification of 5 out of 49 tested cellular off-target sites in this study, rather than zero or many, strongly suggests that Cas9mediated DNA cleavage is not limited to specific targeting of only a 7-12-base-pair target sequence, as suggested in recent studies 10, 11, 18 .
The cellular genome modification data are also consistent with the tradeoff between activity and specificity of sgRNA v1.0 compared to sgRNA v2.1 observed in the in vitro selection data and discrete assays ( Table 1 and Supplementary Table 5 ). The on-target CLTA4-0-1 site had a modification frequency that was sevenfold lower (11% versus 76%) in cells expressing sgRNA:Cas9 v1.0 compared to cells expressing sgRNA:Cas9 v2.1. Although the CLTA4-3-3 and CLTA4-4-8 sites were modified by the sgRNA v2.1:Cas9 complexes, no evidence of modification at any of these three sites was detected in sgRNA v1.0: Cas9-treated cells. The CLTA4-3-1 site, which was modified at 32% of the frequency of on-target CLTA4 site modification in sgRNA v2.1: Cas9-treated cells, was modified at only 0.5% of the on-target modification frequency in sgRNA v1.0-treated cells, representing a 62-fold change in selectivity. Taken together, these results suggest that guide RNA architecture can have a great influence on both Cas9 activity and specificity in cells. Our specificity profiling findings present a potential caveat to recent and ongoing efforts to improve the overall DNA modification activity of guide-RNA:Cas9 complexes through guide RNA engineering 10, 14 .
Overall, the off-target DNA cleavage profiling of Cas9 and subsequent analyses show that (i) guide-RNA:Cas9 recognition extends to 18-20 specified target site base pairs and a two-base-pair PAM for the four target sites tested; (ii) increasing guide-RNA:Cas9 concentrations can decrease DNA-cleaving specificity in vitro; (iii) using more active sgRNA architectures can increase DNA-cleavage activity both in vitro and in cells but also can increase cleavage of off-target sites both in vitro and in cells; and (iv) as predicted by our in vitro results, guide-RNA:Cas9 can modify off-target sites in cells, some of which contain four mutations relative to the on-target site. Our findings provide insights into RNA-programmed Cas9 specificity and reveal a previously unknown role for sgRNA architecture in DNA-cleavage specificity. The principles revealed in this study may also apply to Cas9-based effectors engineered to mediate functions beyond DNA cleavage.
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